Web17 feb. 2024 · The incidence of binding antibodies to Nplate at any time was 9.6% (27/282), of which 2 patients (0.7%) had pre-existing binding non-neutralizing Nplate antibodies at baseline and 11 patients (3.9%) had persistent binding antibody positivity at end of study. Web4 10-draft-labeling-text-word.docx • Monitor the patient carefully throughout the infusion. Certain adverse drug reactions may be related to the rate of infusion.
HIGHLIGHTS OF PRESCRIBING INFORMATION
WebThe recommended dose of Nplate is 10 mcg/kg administered once as a subcutaneous injection. Administer the dose as soon as possible after suspected or confirmed … Web17 feb. 2024 · The use of Nplate to increase survival in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation is based on efficacy … ftse is the stock exchange of which country
HIGHLIGHTS OF PRESCRIBING INFORMATION Discontinue …
WebFDA-approved patient labeling. Revised: 11/2024 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Monitoring 2.3 Dose Modification for Adverse Reactions 2.4 Dose Modification for Drug Interactions 2.5 Discontinuation 3 DOSAGE FORMS AND … WebThe indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. FDA-Approved Indications 1. Nplate is indicated for the treatment of thrombocytopenia in: a. WebFULL PRESCRIBING INFORMATION OPDUALAG ™ (nivolumab and relatlimab-rmbw) 1 INDICATIONS AND USAGE OPDUALAG™ (nivolumab and relatlimab-rmbw) is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. gildan softstyle bleached mockup